12 November 2026 Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.
10 November 2026
9 November 2026
More News
5 November 2026 From November 1, oral proceedings before a Board of Appeal can be audio-recorded and transcribed using artificial intelligence, but any material generated will be kept internal and will not form part of the file or be made available
4 November 2026 AI agents are no longer just helping patent lawyers with their workload. Some are now doing the work themselves. In-house counsel from Insitro, Illumina, 10x Genomics and Invenra discuss how much can be handed over and whether humans could be replaced.
4 November 2026 Joining in Wisconsin, the senior counsel brings “sophisticated” trademark experience and leadership, and counts biotechnology among her sectors.
3 November 2026 With budgets under pressure, counsel from Pfizer, ALX Oncology and BioMarin share how they are reassessing portfolios, trimming costs and prioritising key markets at LSPN Fall.
2 November 2026 New partner joins from Goodwin, where he was a life sciences partner, bringing experience in healthcare transactions, and regulatory and strategic counselling, among other areas.
30 October 2026 With its goal of becoming a global life sciences leader still some way off, the UK is betting on new investment, AI and regulatory changes to help close the gap, according to the government’s autumn budget.
30 October 2026 Mrs Justice Joanna Smith becomes deputy president of the Business and Property Division of the UK High Court, as Sir Colin Birss fills Sir Geoffrey Vos’ shoes as master of the rolls upon his retirement.
Latest Features
Americas
Uncertainty over whether a patent can be challenged through inter partes review at the USPTO has only increased since the discretionary denial policy was introduced, so how should companies plan? Mauricio Uribe and Maria Anderson of Davis Wright Tremaine explain.
Pharma
A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Pharma
Reflecting on decades of patent searching experience, senior scientist on the CAS IP Services team, David Saari, offers insights into the importance of a multidisciplinary approach in today's competitive IP landscape.
MedTech
A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.
Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Europe
Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.
Asia
The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Europe
After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.
Latest Events Videos
Americas
Integrating AI into patent workflows promises efficiency gains, but requires strict oversight regarding accuracy, ethics, and data security. This panel explores the practical realities of deploying AI tools responsibly while maintaining the high standards required in life sciences prosecution.
Americas
Is Brazil moving toward a more predictable patent system, or simply shifting risk? This session examines the far-reaching impact of the ADI 5529 ruling, analysing how the end of automatic patent term extensions is reshaping filing and enforcement strategies.
Regulation & Industry
The post-grant challenge landscape is intensifying on both sides of the Atlantic. This panel analyses recent developments in IPRs, PGRs, EPO oppositions, and the UPC, detailing strategies to simultaneously defend existing portfolios and clear competitive space.
Americas
Choosing between patent protection and trade secrets is a delicate balancing act, especially amid regulatory scrutiny and unpredictable patent office timelines. This session delves into the frontlines of IP strategy, offering practical guidance on when each protection mechanism serves best.